Courtney J Ensslin1, Alyx C Rosen1, Shenhong Wu2, Mario E Lacouture3. 1. Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York. 3. Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: lacoutum@mskcc.org.
Abstract
BACKGROUND: Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus has not been systematically ascertained. OBJECTIVE: A systematic review and meta-analysis of the literature was conducted for axitinib, cetuximab, dasatinib, erlotinib, everolimus, gefitinib, imatinib, ipilimumab, lapatinib, nilotinib, panitumumab, pazopanib, rituximab, sorafenib, temsirolimus, tositumomab, vandetanib, and vemurafenib. METHODS: Databases from PubMed, Web of Science (January 1998 through July 2012), and American Society of Clinical Oncology abstracts (2004 through 2012) were searched. Incidence and relative risk of pruritus were calculated using random- or fixed-effects model. RESULTS: The incidences of all-grade and high-grade pruritus were 17.4% (95% confidence interval 16.0%-19.0%) and 1.4% (95% confidence interval 1.2%-1.6%), respectively. There was an increased risk of all-grade pruritus (relative risk 2.90 [95% confidence interval 1.76-4.77, P < .001]) and variation among different drugs (P < .001). LIMITATIONS: The reporting of pruritus may vary, resulting from concomitant medications, comorbidities, and underlying malignancies. We found a higher incidence of pruritus in patients with solid tumors, concordant with those targeted therapies with the highest pruritus incidences. CONCLUSION: There is a significant risk of developing pruritus in patients receiving targeted therapies. To prevent suboptimal dosing and decreased quality of life, patients should be counseled and treated against this untoward symptom.
BACKGROUND:Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus has not been systematically ascertained. OBJECTIVE: A systematic review and meta-analysis of the literature was conducted for axitinib, cetuximab, dasatinib, erlotinib, everolimus, gefitinib, imatinib, ipilimumab, lapatinib, nilotinib, panitumumab, pazopanib, rituximab, sorafenib, temsirolimus, tositumomab, vandetanib, and vemurafenib. METHODS: Databases from PubMed, Web of Science (January 1998 through July 2012), and American Society of Clinical Oncology abstracts (2004 through 2012) were searched. Incidence and relative risk of pruritus were calculated using random- or fixed-effects model. RESULTS: The incidences of all-grade and high-grade pruritus were 17.4% (95% confidence interval 16.0%-19.0%) and 1.4% (95% confidence interval 1.2%-1.6%), respectively. There was an increased risk of all-grade pruritus (relative risk 2.90 [95% confidence interval 1.76-4.77, P < .001]) and variation among different drugs (P < .001). LIMITATIONS: The reporting of pruritus may vary, resulting from concomitant medications, comorbidities, and underlying malignancies. We found a higher incidence of pruritus in patients with solid tumors, concordant with those targeted therapies with the highest pruritus incidences. CONCLUSION: There is a significant risk of developing pruritus in patients receiving targeted therapies. To prevent suboptimal dosing and decreased quality of life, patients should be counseled and treated against this untoward symptom.
Authors: Mark Agulnik; Ezra W E Cohen; Roger B Cohen; Eric X Chen; Everett E Vokes; Sebastien J Hotte; Eric Winquist; Scott Laurie; D Neil Hayes; Janet E Dancey; Shirley Brown; Gregory R Pond; Ian Lorimer; Manijeh Daneshmand; James Ho; Ming-Sound Tsao; Lillian L Siu Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: Susan L Boone; Alfred Rademaker; Dachao Liu; Carmen Pfeiffer; David J Mauro; Mario E Lacouture Journal: Oncology Date: 2007-12-21 Impact factor: 2.935
Authors: William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg Journal: Clin Cancer Res Date: 2008-01-01 Impact factor: 12.531
Authors: E Van Cutsem; S Siena; Y Humblet; J-L Canon; J Maurel; E Bajetta; B Neyns; D Kotasek; A Santoro; W Scheithauer; S Spadafora; R G Amado; N Hogan; M Peeters Journal: Ann Oncol Date: 2007-09-04 Impact factor: 32.976
Authors: Linda L Garland; Cathryn Rankin; David R Gandara; Saul E Rivkin; Katherine M Scott; Raymond B Nagle; Andres J P Klein-Szanto; Joseph R Testa; Deborah A Altomare; Ernest C Borden Journal: J Clin Oncol Date: 2007-06-10 Impact factor: 44.544
Authors: Andrew X Zhu; Keith Stuart; Lawrence S Blaszkowsky; Alona Muzikansky; Donald P Reitberg; Jeffrey W Clark; Peter C Enzinger; Pankaj Bhargava; Jeffrey A Meyerhardt; Kerry Horgan; Charles S Fuchs; David P Ryan Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405
Authors: Jaxon J Vallely; Kathryn E Hudson; Susan C Locke; Steven P Wolf; Gregory P Samsa; Amy P Abernethy; Thomas W LeBlanc Journal: Support Care Cancer Date: 2019-02-14 Impact factor: 3.603
Authors: Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2017-09-14 Impact factor: 11.527